Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. - Wikidata - awgldk - TriplyDB

Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

http://www.wikidata.org/entity/Q36059811

about

Other targeted drugs in melanoma Targeted therapies in development for non-small cell lung cancer Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis Membrane-Type 1 Matrix Metalloproteinase Downregulates Fibroblast Growth Factor-2 Binding to the Cell Surface and Intracellular Signaling.BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)Resistance to RAF inhibitors revisited.Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages.Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies.Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.The WNT-less wonder: WNT-independent β-catenin signaling.Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling.Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer.Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone.FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.Update on the clinical use of kinase inhibitors in melanoma.Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients.BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1

P2860

Q26775594-12B97A98-0DC8-46A4-8BB5-DEE540261549 Q27022852-1751572E-1C65-4D77-BAAB-B5E4ACB11694 Q30277902-4E65289E-C7D9-4EB8-94C4-7F927D852AC5 Q30365571-603FE15E-7845-4D80-9B84-8DAF4E94C57E Q33757125-057ACE9A-EC1F-43D3-904E-728D7B3BAB15 Q34799472-E37D2999-31CF-425F-AB0F-D937155D3A45 Q35251663-3FC6A3B5-9978-4BB2-8B29-239377CD2EE1 Q35597799-A9EA2F6F-46EE-419D-B5F3-8BC089789A1D Q37301914-0ACC5E46-2ABE-47D6-A2BE-37A873F5DBDA Q37383950-13592C59-FF9E-401D-ADAF-1F0862C8BB78 Q37625751-EF028F74-7020-4658-88C3-1DC4DBE322C3 Q37996468-F5C796B0-0A2D-4082-B784-AE59626B74BF Q38186064-0E50CE9E-DAC0-49F0-A0AE-2E76E94DDADB Q38196881-B1D4DF33-BCF7-4288-B3BB-DB928AAD433E Q38219616-08A9B01C-BBA9-4379-982D-DDFA2907F33D Q38245669-14BA4078-C02B-4B88-AD47-9657394CB967 Q38540713-4F0F666C-2D35-458F-90F3-AE3AB683FD62 Q38867422-38073163-1B97-407D-B108-774CBBAED8E5 Q38959812-5E8A1F48-6A32-4C39-9C23-B85D871F8650 Q39005693-8CE9E52E-6134-487D-B10C-042AD7149DE4 Q39803624-71BE3061-C33D-430B-A156-6B45477C04D6 Q41501598-7F7A9E50-6575-46FD-8B97-A4D2CE9CCC11 Q41701119-7B4B6DD0-6661-4192-9BBB-2341AD67A8B1 Q47143125-23D6D16C-5B6F-4CF8-9E68-870587DDBE1F Q47160915-D0E2D181-4414-41AE-8B8D-E9A288476C3A Q47162061-CF6F72AD-8E59-495E-9A37-EC8488CE92B7 Q47965154-EFC0867E-F239-4D37-9545-3C84B48F42D1 Q54171446-2A227947-7BC5-4C06-AAB9-8BE3CF6EDA2D Q55365778-03D9130E-3C99-49C3-B203-8F65E84BF584 Q58712577-412D6134-87F3-4B74-9D4A-F8926A3BF773

P2860

Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

http://www.wikidata.org/entity/Q36059811

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Fibroblast growth factor recep ...... ynergism with BRAF inhibition.

@ast

Fibroblast growth factor recep ...... ynergism with BRAF inhibition.

@en

type

label

Fibroblast growth factor recep ...... ynergism with BRAF inhibition.

@ast

Fibroblast growth factor recep ...... ynergism with BRAF inhibition.

@en

prefLabel

Fibroblast growth factor recep ...... ynergism with BRAF inhibition.

@ast

Fibroblast growth factor recep ...... ynergism with BRAF inhibition.

@en

P1433

Q36059811-D29493C0-12E2-4543-B398-43A629463E33

P1476

Q36059811-64CBBB23-20D3-4095-BE80-95A1BD823FB1

P2093

Q36059811-04E588D0-36A2-46B3-A15B-4BE7EE014F6D

Q36059811-248A5486-AEE8-415B-A44F-4F10FDCDEF56

Q36059811-38C31C96-FC8B-4C98-8254-05A516532581

Q36059811-4E268533-9BBD-4B90-9C47-A83AB6D8CE74

Q36059811-5ADDFD68-E9FD-4097-AE15-2BBDE5024154

Q36059811-61DF2E52-97C3-4143-B504-CEA2581B9B73

Q36059811-62E06263-81E2-457B-A0F0-293563A44B3A

Q36059811-BD6E6B49-A6CF-4126-B944-F831DE5699F4

Q36059811-BFEB8698-B90C-41BA-82AE-DC5814561B1D

Q36059811-C654E62E-9201-4DE1-ADDA-A534C57D8B31

P2860

Q36059811-066B89D3-525A-4BB0-94A7-906EA4B3A7DB

Q36059811-0C14CA51-1A26-4638-A932-88B7349EE7B2

Q36059811-1297B07C-D1D6-4956-9602-433F66300C4C

Q36059811-1ABB5BBE-B7A6-4A5B-85A8-BB41CD3A99A7

Q36059811-20164672-F0AA-4115-922A-DDA3121F6E1F

Q36059811-2079710C-031A-4C5B-B866-BBFB71DEDBCF

Q36059811-23565DCA-0944-458B-82AA-0F57D41F03C0

Q36059811-2C02EE13-FC69-41FC-AFE5-F175DB99F89F

Q36059811-2C27AB92-CD6F-458C-ABF3-5A58C629038D

Q36059811-2CDC54BF-F330-43E2-821C-C83C38D6B6E8

P2888

Q36059811-2C54A109-9016-4442-A42C-317E69E6D2D3

P304

Q36059811-16E93462-A43A-4B7B-A432-FA4B4A76C655

P31

Q36059811-6675A4F4-F13F-4F63-B648-CD6D2B7CA1B8

P356

Q36059811-D4F19B62-1265-41E0-AE4A-D19CCA0E9E02

P407

Q36059811-70B04BE0-5EF6-4D14-89A4-AA0DEDD1B84E

P433

Q36059811-D6DFE813-EEE4-4C21-8239-1EC0758134E5

P478

Q36059811-2798533B-698F-483A-AF17-71F6F16D2EDA

P50

Q36059811-0B65EB29-BBB1-40A9-A442-418F689F77C1

Q36059811-4FC844DD-5053-4EC6-9999-CB32D4645CEA

Q36059811-810AB6ED-4679-40B5-8049-10F6FB29AB64

Q36059811-9C1C5CE5-6D96-4AD8-ADB9-F2750500FE24

Q36059811-E58439E5-1487-438C-8033-088F00A3E000

P577

Q36059811-B033935F-0302-475B-87A1-4E0E47B92779

P5875

Q36059811-6D792784-E5CD-4481-B5ED-743CDDC99C53

P698

Q36059811-268C5AAC-6289-446E-8924-5EF01689CDDA

P932

Q36059811-B3CD0649-9E15-4449-98D5-3383D11DC710

P356

P1433

Journal of Investigative Dermatology

P1476

Fibroblast growth factor recep ...... ynergism with BRAF inhibition.

@en

P2093

Alexandra Bedeir

http://www.w3.org/2001/XMLSchema#string

Barbara Peter-Vörösmarty

http://www.w3.org/2001/XMLSchema#string

Bettina Grasl-Kraupp

http://www.w3.org/2001/XMLSchema#string

Brigitte Marian

http://www.w3.org/2001/XMLSchema#string

Christine Heinzle

http://www.w3.org/2001/XMLSchema#string

Gerlinde Held

http://www.w3.org/2001/XMLSchema#string

Michael Micksche

http://www.w3.org/2001/XMLSchema#string

Sabine Spiegl-Kreinecker

http://www.w3.org/2001/XMLSchema#string

Sara Ghassemi

http://www.w3.org/2001/XMLSchema#string

Thomas Metzner

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

Mutations of the BRAF gene in human cancer

Sorafenib in advanced hepatocellular carcinoma

Fibroblast growth factors, their receptors and signaling

Deregulation of the activin/follistatin system in hepatocarcinogenesis

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Fibroblast growth factor signalling: from development to cancer

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

P2888

P304

2087-2095

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JID.2011.177

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Christine Pirker

P577

2011-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51489735

http://www.w3.org/2001/XMLSchema#string

P698

21753785

http://www.w3.org/2001/XMLSchema#string

P932

3383623

http://www.w3.org/2001/XMLSchema#string